ArticleMethods in molecular biology (Clifton, N.J.)2018
Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies.
Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The roles of the microtubule cytoskeletal network in cardiac mechanobiology.Journal of cell science · 2026Review
- Heart Scar-In-A-Dish: Tissue Culture Platform to Study Myocardial Injury and Mechanics In Vitro.Journal of biomechanical engineering · 2026Article
- A Novel In Vitro Pathological Model for Studying Neural Invasion in Non-Melanoma Skin Cancer.Gels (Basel, Switzerland) · 2024Article
- Single-Cell Analysis of Contractile Forces in iPSC-Derived Cardiomyocytes: Paving the Way for Precision Medicine in Cardiovascular Disease.International journal of molecular sciences · 2023Article
- A Workflow to Produce a Low-Cost In Vitro Platform for the Electric-Field Pacing of Cellularised 3D Porous Scaffolds.ACS biomaterials science & engineering · 2023Article
- Recent advances in biological pumps as a building block for bioartificial hearts.Frontiers in bioengineering and biotechnology · 2023Review
- Rianú: Multi-tissue tracking software for increased throughput of engineered cardiac tissue screening.Computer methods and programs in biomedicine update · 2023Article
- PPARdelta activation induces metabolic and contractile maturation of human pluripotent stem cell-derived cardiomyocytes.Cell stem cell · 2022Article
- A micromachined force sensing apparatus and method for human engineered cardiac tissue and induced pluripotent stem cell characterization.Sensors and actuators. A, Physical · 2021Article
- Engineering spatial-organized cardiac organoids for developmental toxicity testing.Stem cell reports · 2021Article
- Engineering and Assessing Cardiac Tissue Complexity.International journal of molecular sciences · 2021Review
- Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling.Frontiers in cardiovascular medicine · 2021Review
- Beyond Family: Modeling Non-hereditary Heart Diseases With Human Pluripotent Stem Cell-Derived Cardiomyocytes.Frontiers in physiology · 2020Review
- Adult human cardiac stem cell supplementation effectively increases contractile function and maturation in human engineered cardiac tissues.Stem cell research & therapy · 2019Article
- Biomaterializing the promise of cardiac tissue engineering.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The lack of biomimetic in vitro models of the human heart has posed a critical barrier to progress in the field of modeling cardiac disease. Human engineered cardiac tissues (hECTs)-autonomous, beating structures that recapitulate key aspects of native cardiac muscle physiology-offer an attractive alternative to traditional in vitro models. Here we describe the use of hECTs to advance our understanding and modeling of cardiac diseases in order to test therapeutic interventions, with a focus on contractile dysfunction in the setting of inherited and acquired forms of cardiomyopathies. Four major procedures are discussed in this chapter: (1) preparation of hECTs from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) on single-tissue and multitissue bioreactors; (2) data acquisition of hECT contractile function on both of these platforms; (3) hECT modeling of hereditary phospholamban-R14 deletion-dilated cardiomyopathy; and (4) cryo-injury and doxorubicin-induced hECT models of acquired cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.